Austria vs Dominican Republic: Statin use vs. average non-HDL cholesterol levels
Austria
3.6
in 2018
Dominican Republic
3.6
in 2018
Austria rank
30th
Dominican Republic rank
30th
Statin use vs. average non-HDL cholesterol levels over time
- Austria
- Dominican Republic
How they compare
Austria currently reports 3.6 against 3.6 in Dominican Republic, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Austria ahead.
Austria ranks 30th and Dominican Republic ranks 30th of 191 countries.
Austria has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Austria | Dominican Republic | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.48 | 3.4 | 1.08 | Austria |
| 1990s | 4.29 | 3.4 | 0.89 | Austria |
| 2000s | 3.95 | 3.45 | 0.5 | Austria |
| 2010s | 3.7 | 3.57 | 0.1333 | Austria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Austria or Dominican Republic?
- Austria, at 3.6 against 3.6 in Dominican Republic as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Austria and Dominican Republic?
- 0, with Austria ahead.
- How many years of comparable data are there for Austria and Dominican Republic?
- 39 years are reported by both, from 1980 to 2018.
- How do Austria and Dominican Republic rank globally for statin use vs. average non-hdl cholesterol levels?
- Austria ranks 30th and Dominican Republic ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.